1h Free Analyst Time
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Bcl-2-like protein 1 is a protein encoded by the BCL2L1 gene. It belongs to BCL-2 family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulate cell death by blocking the voltage-dependent anion channel by binding to it and preventing the release of the caspase activator (CYC1) from the mitochondrial membrane. It acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.Speak directly to the analyst to clarify any post sales queries you may have.
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 3 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease and Musculoskeletal Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Hepatocellular Carcinoma, Small-Cell Lung Cancer, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Bladder Cancer, Blood Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelomonocytic Leukemia (CMML), Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Fibrosis, Follicular Lymphoma, Gastric Cancer, Head And Neck Cancer, Hematological Tumor, Hormone-Sensitive Prostate Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lymphoblastic Lymphoma, Mantle Cell Lymphoma, Metastatic Melanoma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Myelodysplastic Syndrome, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroendocrine Tumors, Nodal Marginal Zone B-Cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Sezary Syndrome, Splenic Marginal Zone B-Cell Lymphoma, T-Cell Lymphomas and Unspecified B-Cell Lymphomas.
The latest report, outlays comprehensive information on the Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)
- The report reviews Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Overview
- Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Companies Involved in Therapeutics Development
- AbbVie Inc
- Ascenta Therapeutics Inc
- Ascentage Pharma Group International
- AstraZeneca Plc
- Dialectic Therapeutics Inc
- Sirnaomics Ltd
- Zentalis Pharmaceuticals Inc
- Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Drug Profiles
- 753B - Drug Profile
- Product Description
- Mechanism Of Action
- ABT-737 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AT-101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AZD-0466 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BCL-xL Degrader - Drug Profile
- Product Description
- Mechanism Of Action
- DT-2216 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- navitoclax dihydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- pelcitoclax - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections - Drug Profile
- Product Description
- Mechanism Of Action
- STP-369 - Drug Profile
- Product Description
- Mechanism Of Action
- Vaccine for Hormone-Sensitive Prostate Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Dormant Products
- Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Discontinued Products
- Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Product Development Milestones
- Featured News & Press Releases
- Jun 10, 2022: AbbVie presents investigational Navitoclax preliminary data in JAK inhibitor Naïve myelofibrosis patients
- Apr 28, 2022: Ascentage Pharma to present data on APG-1252 at the 2022 American Society of Clinical Oncology Annual Meeting
- Apr 13, 2022: AbbVie reports positive data from Phase II myelofibrosis therapy trial
- Mar 14, 2022: Dialectic Therapeutics announces DT2216 has received orphan drug designation from the FDA for the treatment of T-Cell lymphoma
- Dec 14, 2021: Ascentage Pharma presents on pelcitoclax at the 63rd American Society of Hematology (ASH) Annual Meeting
- Nov 04, 2021: Ascentage Pharma to release latest data from pelcitoclax including a Chinese study demonstrating complete response
- Sep 13, 2021: Ascentage Pharma announces latest data of its investigational Bcl-2/Bcl-xL inhibitor pelcitoclax (APG-1252) combined with osimertinib in patients with EGFR TKI-resistant non-small cell lung cancer
- Sep 08, 2021: Ascentage Pharma announces latest data of its investigational Bcl-2/Bcl-xL inhibitor Pelcitoclax (APG-1252) combined with Osimertinib in patients with EGFR TKI-resistant non-small cell lung cancer
- Aug 20, 2021: Dialectic Therapeutics receives $14.4 million Texas Company Product Development Research Award from the Cancer Prevention & Research Institute of Texas
- May 19, 2021: Ascentage Pharma announces presentation on pelcitoclax at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
- Apr 21, 2021: Ascentage Pharma to present data on pelcitoclax (APG-1252) at 2021 ASCO Annual Meeting
- Apr 12, 2021: Ascentage Pharma releases preclinical data on Pelcitoclax at AACR Annual Meeting 2021
- Mar 03, 2021: Dialectic Therapeutics receives FDA clearance of IND application for lead antiapoptotic protein targeted degradation (APTaD) candidate DT2216
- Feb 09, 2021: AZD0466 clinical DEP program global expansion
- Oct 08, 2020: Ascentage Pharma's apoptosis-targeting drug candidate granted Orphan Drug Designation by the US FDA
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by AbbVie Inc, 2022
- Pipeline by Ascenta Therapeutics Inc, 2022
- Pipeline by Ascentage Pharma Group International, 2022
- Pipeline by AstraZeneca Plc, 2022
- Pipeline by Dialectic Therapeutics Inc, 2022
- Pipeline by Sirnaomics Ltd, 2022
- Pipeline by Zentalis Pharmaceuticals Inc, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Ascenta Therapeutics Inc
- Ascentage Pharma Group International
- AstraZeneca Plc
- Dialectic Therapeutics Inc
- Sirnaomics Ltd
- Zentalis Pharmaceuticals Inc
